v3.25.4
Segment Reporting - Schedule of Segment Profit or Loss, Including Significant Segment Expenses (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenues [Abstract]    
Total revenues $ 2,036 $ 6,235
Research and development expenses    
Total claseprubart program-related expenses 72,072 54,395
Total research and development expenses 145,638 83,105
General and administrative expenses    
Total general and administrative expenses 34,331 24,994
Other income, net 15,596 16,895
Net Income (Loss) (162,337) (84,969)
License [Member]    
Revenues [Abstract]    
Total revenues 2,036 326
Clinical operation activities [Member]    
Research and development expenses    
Total claseprubart program-related expenses 49,870 25,764
CMC activities [Member]    
Research and development expenses    
Total claseprubart program-related expenses 16,570 19,494
Preclinical study costs [Member]    
Research and development expenses    
Total claseprubart program-related expenses 3,563 8,537
Personnel and Related Costs [Member]    
Research and development expenses    
Total research and development expenses 26,008 16,638
General and administrative expenses    
Total general and administrative expenses 11,531 8,249
Share Based Compensation [Member]    
Research and development expenses    
Total research and development expenses 10,090 5,576
General and administrative expenses    
Total general and administrative expenses 12,703 7,318
Discovery Expenses [Member]    
Research and development expenses    
Total research and development expenses [1] 32,070 2,117
Other costs [Member]    
Research and development expenses    
Total claseprubart program-related expenses 2,069 600
Total research and development expenses 5,398 4,379
General and administrative expenses    
Total general and administrative expenses 10,097 9,427
Related Party [Member] | License [Member]    
Revenues [Abstract]    
Total revenues $ 0 $ 5,909
[1]

For the year ended December 31, 2025, discovery expenses include $30.0 million related to the upfront and near-term milestone payments pursuant to the Leads License Agreement (as defined below in Note 16) related to DNTH212. Additional information is included in Note 16.